Fundraising FoxVida Ventures — 2021 Investments
3 investments dated 2021 · listed companies and verified rows first · show all
Kyverna is a clinical-stage biopharmaceutical company developing CAR T-cell therapies to treat autoimmune diseases through B cell depletion and immune system reset.
BiotechEmeryville, US
Warner Biddle(Chief Executive Officer)inBrian Kotzin(Director)Ian Clark(Director)Ryan Jones(Executive Officer)Karen Walker(Executive Officer)Peter Maag(Executive Officer, Director)in
Co-investorsBain Capital Life SciencesWestlake Village BioPartnersGilead SciencesInsight PartnersKleiner PerkinsNorthpond Ventures+3 more
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)inRyan B. Corcoran(Director, Promoter)Richard Heyman(Founder)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersNextech InvestOrbiMedDigitalis VenturesNVIDIA
Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.
BiotechHealthtech
Co-investorsAdvent Life SciencesEcoR1 CapitalForesite CapitalGeneral AtlanticLifeSci Venture PartnersMedicxi+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.